UbiVac, Inc.

DUBLIN, June 27, 2023 /PRNewswire/ -- The "Cancer Vaccine Markets, 2023-2030." report has been added to ResearchAndMarkets.com's offering. The global cancer vaccine market was valued at USD 5.75 billion in 2022, and is predicted to reach USD 13.4 billion by 2030, with a CAGR of 10.7% during the forecast period, 2023 to 2030. Growth in incidences of cancer across the globe, owing to high consumption of tobacco and alcohol, along with an unhealthy diet and infections is expected to fuel the cancer vaccine market growth. However, longer timelines hinder growth of the market. On the contrary, use of nanosensors in diagnosing cancer, which include oral fluid nanosensor test (OFNASET), is expected to create ample opportunities for key players operating in the market. Market Dynamics Drivers Increase in the Prevalence of Cancer Across the Globe Growing Government, and International Organization Initiatives to Eliminate Cancer Restraints Longer Timeline Process and High Cost Opportunities Technological Advancement in Healthcare Sectors Segment Overview The global cancer vaccine market is segmented on the basis of technology, type, disease indication, end-user, and region. By technology, the market is classified into dendritic cells, recombinant vaccines, antigen/adjuvant vaccines, whole cell vaccines, and viral & DNA vaccines. By type, the market is segmented into preventive vaccines and therapeutic vaccines. By disease indication, the market is categorized into cervical cancer, prostate cancer, and others. By end-user, the market is divided into pediatrics and adults. Region wise, the market is segmented into North America, Europe, Asia-Pacific, and RoW. Regional Analysis North America estimated to hold a dominant share of the market North America dominates the cancer vaccine market and is potently expected to remain dominant throughout the forecast period. Rise in awareness regarding health among educated population has led to early diagnosis of cancer, which boosts the market growth. For instance, the Government of Canada announced that around 27,400 women were diagnosed with breast cancer in 2020. This early detection of cancer helps women to undergo treatment at the early stage, which, in turn, propels the market growth. Growth in R&D in the region, owing to collaboration among well-known big tech companies and cancer research centers for developing cancer vaccines further propel the market growth. For instance, in July 2022, Amazon collaborated with Fred Hutchinson Cancer Research Center to develop cancer vaccines for breast cancer and melanoma. Fred Hutch received permission from the U.S. Food and Drug Administration to proceed with a Phase I clinical trial. Amazon contributed scientific and machine learning expertise to a partnership with Fred Hutch to explore development of personalized treatment for certain forms of cancer. Key Market Players Emerging and efficient key players in the cancer vaccine market research include companies such as: GlaxoSmithKline PLC UbiVac, Inc. Biontech, Dendreon Pharmaceuticals, Inc. Dynavax Technologies Corporation Merck & Co. Inc. Imugene Limited Moderna, Inc. Northwest Biotherapeutics, Inc. Oxford Vacmedix Recent Developments August 2022 Merck joined hands with Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies. The agreement will help in discovering, developing, and commercializing multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. May 2022 Imugene Limited and City of Hope, one of the largest cancer research and treatment organizations in the United States, announced Phase 1 clinical trial to evaluate safety of novel cancer-killing virus CF33-hNIS VAXINIA. It is used in people with advanced solid tumors. June 2022 GlaxoSmithKline plc acquired Sierra Oncology, Inc., to develop targeted therapies for treatment of rare forms of cancer that includes Myelofibrosis. This acquisition aims at the development of vaccines and medicines. January 2022 Dynavax Technologies Corporation announced that Shingles vaccine is in initiation Phase 1 clinical trials. This vaccine is helpful in treating a herpes zoster virus, along with undergoing treatment for cancer patients. It treats cancer patients that are at the risk of developing shingles. June 2020 UbiVac collaborated with Bristol Myers Squibb to evaluate the tolerability, safety, and preliminary efficacy of DPV-001. DPV-001 is a cancer vaccine that instructs immune system to destroy cancer cells. Report Scope: Key Benefits The cancer vaccine market report provides quantitative analysis of the current market and estimations from 2023 to 2030, which assists in identifying the prevailing market opportunities. The study comprises a deep dive analysis of the cancer vaccine market including current and future trends to depict prevalent investment pockets in the market. Information related to key drivers, restraints, and opportunities and their impact on the cancer vaccine market is provided in the report. Competitive analysis of the market players, along with their market share in the cancer vaccine market is provided in the report. SWOT analysis and Porters Five Forces model is elaborated in the study. Value chain analysis in the market study provides a clear picture of role of stakeholders. Key Topics Covered 1. Introduction 2. Cancer Vaccine Market- Executive Summary 3. Market Overview 4. Market Share Analysis 5. Global Cancer Vaccine Market, by Technology 6. Global Cancer Vaccine Market, by Type 7. Global Cancer Vaccine Market, by Indication 8. Global Cancer Vaccine Market, by End-use 9. Global Cancer Vaccine Market, by Region 10. Company Profiles For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

None  Welcome to this week's (and last week's) Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Ginkgo BioWorks CEO, ex-Google head plucked for federal biotech commission  The National Security Commission on Emerging Biotechnology   Ginkgo BioWorks CEO and co-founder Jason Kelly, Ph.D., has been selected to lead a 12-member group assessing emerging biotech innovation for the U.S. Department of Defense. The commission’s main focus will be reviewing how biotech advancements and related tech can help shape department activities. After one year, the commission is meant to produce an interim report for the U.S. President Joe Biden and the Armed Services Committees. The end goal is providing a final, unclassified report within two years, including recommendations for action by Congress and the federal government. Michelle Rozo, Ph.D., was chosen to serve as vice chair for the commission. She was previously Director of Technology and National Security at the National Security Council, where she advised the president on biotech and national security policy.  Google’s former CEO Eric Schmidt, Ph.D., who serves as a strategic adviser and founding nonmanaging partner for VC First Spark Ventures, has also been appointed to the commission. However, members of the newly formed group don’t have to divest their own personal biotech investments, which could potentially allow members to profit if their companies receive new federal biotech spending, according to a CNBC report.  The other appointed commissioners are: national security expert Paul Arcangeli; Oklahoma's 5th Congressional District Representative Stephanie Bice; materials scientist and biological engineer Angela Belcher, Ph.D.; California’s 17th Congressional District Representative Ro Khanna; former CIA executive Dawn Meyerriecks; California Senator Alex Padilla; former Assistant Director for Biotechnology in the Office of the Under Secretary of Defense for Research & Engineering Alexander Titus, Ph.D.; Indiana Senator Todd Young; and senior adviser and defense expert Dov Zakheim, Ph.D. Release BMS exec set to depart this summer  Bristol Myers Squibb Rupert Vessey, who came into the Bristol Myers Squibb orbit with the 2019 acquisition of Celgene, is set to retire effective July 3. BMS CEO Giovanni Caforio, M.D., announced the departure at the top of the company’s fourth-quarter earnings call Thursday. Vessey is executive vice president and president of research and early development. He joined Celgene in 2015, serving as president of the research and early development organization. Prior to that, he held roles at Merck & Co. and GSK. “Rupert led the successful integration of research and the development of a strong pipeline across all stages of development,” Caforio said. Vessey’s name has cropped up in a number of BMS’ recent transactions, including the $905 million licensing deal with BridgeBio and the third collaboration with immunotherapy drug discovery biotech Immatics that could be worth as much as $4.2 billion down the line. Taking over for Vessey as executive vice president and chief research officer will be Robert Plenge, M.D., Ph.D., who has served as head of the Immunology, Cardiovascular and Fibrosis Thematic Research Center and head of translational medicine. Webcast Roche picks insider for top pharma job Roche The Big Pharma is mixing up its leadership team, selecting current Head of Global Product Strategy Teresa Graham to helm Roche’s pharma group as CEO. Starting next month, Graham will replace Thomas Schinecker, who has served as interim leader since Bill Anderson’s departure at the end of 2022. For his part, Schinecker is set to become CEO of the entire Roche group this March. Graham has been with Roche for nearly four years and will take over as COVID product sales across pharma and diagnostics drop due to declining demand. Before Roche, Graham spent more than 14 years at Genentech until the company was acquired by Roche.  At the same time, Roche is promoting Levi Garraway, M.D., Ph.D., chief medical officer, to the executive committee. Fierce Pharma > T-cell therapy company BlueSphere Bio has tapped former Takeda exec Erkut Bahceci, M.D., to serve as the company’s chief medical officer. Before serving as Takeda’s SVP and head of oncology development, he worked at Astellas for a decade in roles of increasing responsibility up to the head of clinical science of hematologic malignancies. Before Astellas, Bahceci worked at Bristol Myers Squibb and Bayer. Release   > Wilson Bryan, M.D., the FDA’s director of the office of tissues and advanced therapies at the Center for Biologics Evaluation and Research, will be retiring in March of this year, the FDA confirmed with Fierce Biotech.    > Texas-based Taysha Gene Therapies is parting with another executive, this time the company’s chief medical officer Suyash Prasad. Prasad’s exit came only a week or so after RA Session II resigned, though Session still holds on to his founder and board member titles. Before Taysha, Prasad held roles at BioMarin Pharmaceuticals, Genzyme and Eli Lilly, among others. Release      > Merck’s Joseph Eid, M.D., has left the Big Pharma for biotech, joining Dragonfly Therapeutics as president of R&D. While at Merck, he helped lead the development of pembrolizumab, also known as Keytruda. Before Merck, Eid also worked at BMS and Roche. Release > Nadège Pelletier, Ph.D., will be taking the chief scientific officer reins from Tom Evans, Ph.D., at Vaccitech. Evans is retiring after six years with the clinical-stage company. As for Pelletier, she joins from the Novartis Institutes for Biomedical Research and has also worked at Roche in its research and early development arm. Release > Kevin D’Amour, Ph.D., has joined Stemson Therapeutics as the cell therapy company’s chief scientific officer. Before joining Stemson, D’Amour spent nearly two decades at ViaCyte, which was acquired by Vertex in 2022. Release  > Athira Pharma’s Kevin Church, Ph.D., has been promoted to serve as the clinical-stage company’s chief scientific officer. Church joined the company focused on neurodegeneration diseases in 2016 and most recently served as EVP of research. Release  > Starting April 1, Anton (Tony) Hoos, M.D., Ph.D., will head up R&D and medical affairs and also serve as chief medical officer for Swedish Orphan Biovitrum (Sobi). Hoos will replace Anders Ullman, M.D., Ph.D. who is set to retire. The incoming CMO carries more than three decades of industry experience, including positions at Amgen, GSK and Aventis. Release > Hansa Biopharma has started the hunt for a new chief scientific officer after CSO and Chief Operating Officer Christian Kjellman announced plans to leave in 2024. Kjellman has been with the company since 2008, taking on the dual leadership role in 2020. Release > Oncology biotech Ariceum Therapeutics has brought on Germo Gericke, M.D., to serve as the company’s chief medical officer. Germo joins from Novartis’ Advanced Accelerator Applications, where he held positions of chief medical officer and head of R&D. Release > vTv Therapeutics is welcoming Elizabeth Keiley as EVP and general counsel. She most recently served as general counsel for Entasis Therapeutics. Before that, she also held leadership positions at Oxford Immunotec and Zimmer. Release > Will Kane is leaving his spot as EVP and chief commercial officer at BioXcel Therapeutics for Karuna Therapeutics, a clinical-stage company aiming to develop medicines for psychiatric and neurological conditions. Kane will take on the role starting Feb. 6. The leader has held senior level commercial positions at Allergan, Pfizer, and Sepracor (now Sunovion Pharmaceuticals) and helped launch several successful brands including Namzaric‎ for Alzheimer’s disease, Vraylar for schizophrenia and bipolar disorder, and Ubrelvy for migraines. Release > Ring Therapeutics has called on Christopher Wright, M.D., Ph.D., to serve as chief medical officer and head of translational research, starting Feb. 7. Before Ring, Wright was CMO at AavantiBio, which was recently acquired by Solid Biosciences. He has also held leadership roles at Cyclerion, Ironwood Pharmaceuticals, Axcella Health and Vertex Pharmaceuticals. Release > Clinical-stage Adrenomed has tapped Stephan Witte, M.D., to serve as the company’s chief medical officer. Before Adrenomed, Witte was VP of clinical science and operations at Atriva Therapeutics and has also held positions at Breath Therapeutics, Inotrem and Helion Pharma. Release > Ambrx Biopharma has appointed Sandra Aung, Ph.D., to serve as the company’s EVP and head of clinical development. Aung most recently served as OncoSec’s SVP and has years of experience across Fate Therapeutics, HUYA Bioscience International, Nektar Therapeutics, Prometheus Laboratories, UbiVac and Cell Genesys, among others. Release > Roger Sidhu, M.D., has hopped aboard Treadwell Therapeutics, joining the team as chief medical officer. Sidhu was most recently CMO at Brooklyn (now Eterna) ImmunoTherapeutics and has held past roles at Roivant Sciences, Cell Design Labs (acquired by Gilead subsidiary Kite) and Amgen. Release > Two decades after founding Know Labs—then known as Visualant—Ron Erickson is once again stepping into the role of CEO. He’s replacing Phil Bosua, who had served as CEO of the tech developer since early 2018. Though Bosua stepped down, he’ll stick around as a technology adviser and consultant. As for Erickson, he helmed Know Labs between 2003 and 2004 and took on the top job once again at the end of 2009 until Bosua replaced him. The company also announced a handful of other executive changes, including Masanori King Takee, who has been at Know Labs since 2018, was named chief technology officer. Leo Trautwein, meanwhile, is transitioning from his previous title of chief marketing officer to serve as chief commercial officer. He’s been replaced as marketing head by Jessica English, previously the VP of brand at health-tracking ring maker Oura. Fierce Biotech > Clinical-stage biotech TC BioPharm has hired Bree Harlin to serve as chief clinical officer. Harlin most recently worked at Eli Lilly’s Loxo Oncology, where she helped with the clinical development of targeted therapies for various types of solid and hematologic cancers. Release  > Poseida Therapeutics’ executive chair Eric Ostertag, M.D., Ph.D., is resigning. The founding Poseida CEO helped lead the company, alongside spinout Transposagen, for nearly 20 years. Release > Aprea Therapeutics’ former president and CEO Christian Schade has joined Flagship Pioneering as a growth partner to help scale and grow Flagship-founded companies. Release

SAN DIEGO--(BUSINESS WIRE)-- Ambrx, Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody-drug conjugates (ADCs), has appointed Sandra Aung, Ph.D., as Executive Vice President, Head of Clinical Development. Dr. Aung will assume all clinical development leadership responsibilities of Ambrx’s proprietary pipeline of several ADC product candidates. Dr. Aung brings over 20 years of experience in the pharmaceutical and biotechnology industry having led oncology-focused clinical development teams and projects in companies of different sizes. Dr. Aung has a versatile background in autoimmunity, immune-oncology, and infectious disease and has authored over 20 peer-reviewed publications and received multiple Small Business Innovate Research (SBIR) grants from the National Cancer Institute/ National Institutes of Health (IH/NCI) for her work in immune-oncology drug development. Dr. Aung helped lead Nektar Therapeutics' lead clinical compound, pegylated interleukin-2 (IL-2) (bempeg), from First-In-Human studies to multiple Phase 3 registrational trials in less than 3 years. Dr. Aung's cross industry and academic relationships with KOLs and more importantly expertise with high dose IL-2 (Proleukin®) were instrumental for this success. Dr. Aung's extensive immuno-oncology drug development experience additionally comes from previous research and leadership positions she held at UbiVac, Inc. and Cell Genesys, Inc. Dr. Aung earned her Ph.D. in microbiology and immunology from Vanderbilt University and performed her post-doctoral research at The Scripps Research Institute. "The addition of Sandra comes at a pivotal moment as we seek to demonstrate the superiority of our proprietary ADC conjugation technology and improved safety and efficacy in multiple clinical trials,” said Daniel O'Connor, President and Chief Executive Officer of Ambrx. "Sandra’s extensive scientific and clinical experience in successfully advancing cancer treatments, together with her strong relationships with clinical investigators and key opinion leaders in oncology makes her the ideal executive to lead our clinical development programs. We are extremely excited to welcome her to the leadership team at this important time for our Company." About Ambrx Biopharma, Inc. Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit . Forward-Looking Statements This press release includes certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “intend,” “plan,” and similar expressions, and include, without limitation, express or implied statements regarding Ambrx’s clinical trial and product candidate strategy and expectations and the superiority of the Company’s proprietary ADC conjugation technology. Forward-looking statements are based on Ambrx’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the continuing impact of the COVID-19 pandemic and other public health-related risks and events on Ambrx’s business, operations, strategy, goals and anticipated milestones; Ambrx’s ability to execute on its strategy including with respect to the timing of its R&D efforts, initiation of clinical trials and other anticipated milestones; risks associated with development of novel therapeutics, including potential delays in clinical trials and regulatory submissions and the fact that future clinical trial results may not be consistent with preliminary results or results from prior preclinical studies or clinical trials; Ambrx’s ability to fund operations as anticipated; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Ambrx’s Annual Report on Form 20-F filed with the SEC on April 26, 2022, and elsewhere in Ambrx’s filings and reports with the SEC. Forward-looking statements contained in this press release are made as of this date, and Ambrx undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.